SCHEMBL2632253

SCHEMBL2632253

Cc1ccc(-c2cn3cc(/C(N)=N/O)ccc3n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 12/20 0.60
ALDH1A1 P00352 12/20 0.60
RAB9A P51151 11/20 0.60
KDM4E B2RXH2 9/20 0.60
SMN1; SMN2 Q16637 8/20 0.60
KMT2A Q03164 3/20 0.60
PAX8 Q06710 2/20 0.60
MEN1 O00255 2/20 0.60
MITF O75030 1/20 0.60
KDM5A P29375 1/20 0.60
KDM5C P41229 1/20 0.60
ALDH1A3 P47895 4/20 0.54
SLC2A1 P11166 1/20 0.54
APP P05067 2/20 0.51
POLB P06746 4/20 0.49
GAA P10253 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
LMNA P02545 2/20 0.49
STAT3 P40763 1/20 0.49
CASP3 P42574 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2127102 1.00 NPC1 (0.60) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL2126832 0.88 ALDH1A3 (0.55) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL14046610 0.87 ALDH1A3 (0.56) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL14028702 0.86 ALDH1A3 (0.58) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL2632304 0.84 APP (0.46) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL2128034 0.84 APP (0.46) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL8866583 0.84 ALDH1A1 (0.62) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL8865941 0.82 ALDH1A1 (0.66) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL14028701 0.80 ALDH1A3 (0.51) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2
SCHEMBL2129032 0.78 ALDH1A1 (0.73) NPC1ALDH1A1RAB9AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
US-8399476-B2 Imidazo[1,2-a]pyridines and their use as pharmaceuticals SANOFI (FR) 2013-03-19 US disclosed
EP-2129375-B1 IMIDAZO[1,2-A]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2012-04-25 EP disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-05-06 US disclosed
WO-2008104278-A1 IMIDAZO[1,2-A] PYRIDINES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-09-04 WO disclosed
EP-1964840-A1 Imidazo[1,2-a]pyridines and their use as pharmaceuticals sanofi-aventis (FR) 2008-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113412-A1 IMIDAZO[1,2-a]PYRIDINES AND THEIR USE AS PHARMACEUTICALS NOS1, PTGIS, NOS2 NPC1 2959/4885ALDH1A1 1286/4885RAB9A 2234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.